RUNX3 and Barrett esophagus: In background studies performed at Johns Hopkins University and validation studies at Previse, four specific methylation markers (p16, RUNX3, HPP1, and FBN1) have demonstrated consistent statistically significant performance as early harbingers of neoplastic progression in BE, presenting an opportunity for improved prognostication in BE patients [23,24,25,26].